-
I, too, was looking forward to Vyvgart entering the market. I patiently followed the phase 3 clinical trial, which showed excellent results with seronegative MG patients. Thank I was shocked when the FDA approved its use in seropositive patients only. My Neurologist was also shocked as he is treating a few seronegative MG patients and this could have been a game changer.
I was so upset that I called the Vyvgart Customer Support line and voiced to them that those of us who are seronegative, are very disappointed and feel ignored. I explained the MG community communicates heavily on various forums and are all saying the same thing…disappointment and feel our patient population is being ignored. The representative, who was well versed and dedicated to the Vyvgard support role, promised she would get the message to corporate.
I’m bummed, but my Neurologist told me he’d keep a close eye on results with other patients, but more importantly, it must start being approved for reimbursement by our insurance companies and Medicare part D. Who knows how long this will take.
It may help if others start voicing disappointment directly to the company, as I have. Squeaky wheels and all that!